A federal vaccine advisory panel remade under Health Secretary Robert F. Kennedy Jr. voted last September to remove recommendations for the combined measles, mumps, rubella and varicella shot for young children. A new analysis in JAMA Network Open says the change is likely to fall hardest on toddlers with the least room for missed appointments and extra clinic visits.
The vaccine, known as MMRV, combines protection against measles, mumps, rubella and chickenpox in one injection. The more common approach gives the measles, mumps and rubella vaccine and the chickenpox vaccine as two separate shots at the same visit, often written as MMR+V.
The Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention panel that sets federal vaccine recommendations, voted to drop MMRV from its recommendations without using the standard decision framework the committee has historically used to assess the practical effects of a change, according to the JAMA Network Open authors and an accompanying commentary.
The consequences are not just semantic. Once ACIP removed the recommendation, private insurers were no longer required to cover MMRV. The shot also became unavailable through the federal Vaccines for Children program, which provides vaccines to roughly half of U.S. children and is aimed largely at low-income families.
Who was using the combined shot
Researchers in Washington state reviewed immunization records for more than 200,000 children ages 12 to 47 months in King County, which includes Seattle, from 2015 through 2025. They found that a little more than 31,000 children, about 15 percent, received MMRV during that period.
That local share matches national use described in the study: MMRV has been a minority option, while most children receive MMR and varicella separately. Its use in King County stayed at about 15 percent across the decade, despite prior guidance that preferred MMR+V for the first dose.
The group receiving MMRV was not random. The researchers found that children who received MMRV as a first dose were more likely than other vaccinated children to be from minority racial and ethnic groups. They were also more likely to receive a catch-up dose between 16 and 47 months, after the usual 12-to-15-month window.
Children who received MMRV were more than three times as likely as other vaccinated children to be eligible for the federal free-vaccine program, and nearly four times as likely to be vaccinated at a safety-net clinic, according to the study.
The researchers concluded that this population “might be at risk of not receiving recommended vaccines if options become limited.” That is the boring, operational part of vaccine policy that tends to matter more than committee theater: fewer shots and fewer visits can be the difference between completing a series and falling out of care.
Why MMRV was already a second-choice option
MMRV was approved by the Food and Drug Administration in 2005. Later analyses found a small increase in febrile seizures when it was used as the first of two recommended doses in children 12 to 15 months old. The increase was not seen for the second dose, recommended at ages 4 to 6.
Those analyses found 7 to 8.5 febrile seizure cases per 10,000 first-dose MMRV vaccinations, compared with 3.2 to 4.2 cases per 10,000 first-dose MMR+V vaccinations. That amounts to about one additional febrile seizure for every 2,300 to 2,600 children vaccinated with MMRV.
Febrile seizures are seizures associated with fever and are generally followed by full recovery without long-term effects, according to the study discussion. By age 5, about 5 percent of children have had one from some cause, such as influenza or an ear infection.
Because of the seizure signal, ACIP in 2009 preferred MMR+V over MMRV for first doses while leaving MMRV available as a safe and effective option for parents and clinicians. The new study says no new evidence has changed that expert view.
In a commentary published with the study, AcademyHealth policy experts Elizabeth Cope and Aaron Carroll wrote that the findings were “not surprising,” because combination vaccines can reduce injections, visits and cost barriers. They said those benefits matter most for families dealing with hourly work, lack of paid leave and follow-up appointments that may not happen.
Cope and Carroll noted that the study covered one county in one state, a real limitation. They added that if the same pattern appears in less-resourced settings, the equity effects could be larger. They did not claim the public record proves Kennedy’s views drove the ACIP vote, but wrote that several safeguards meant to protect ACIP independence were absent at the same time.
This story draws on original reporting from Ars Technica.
